Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma

Carol M Richman, E. Podczaski, P. A. Weiser, A. L. Herbst

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Thirty-six patients with advanced/recurrent epithelial ovarian carcinoma were treated with a combination of hexamethylmelamine, cyclophosphamide, adriamycin, and cis-platinum. In the group of 23 previously untreated patients, 10 of 12 (83%) with measurable disease had objective responses (7 complete, 3 partial). The median survival of the 23 patients exceeded 18 months. After approximately 1 year of chemotherapy, 9 patients with no clinical evidence of disease had a 'second look' laparotomy; 6 of these patients were disease-free. Two of the 6 patients with surgically documented complete responses had bulky ( > 5 cm) disease prior to initiation of chemotherapy and remained disease-free at 22 and 50 months. One of the 6 patients relapsed 5 months after a negative second look. The other patients were alive and disease-free at 18, 46, and 51 months. Only 4 of 13 melphalan-resistant patients (31%) demonstrated an objective response to the 4-drug combination. The median survival was 13 months.

Original languageEnglish (US)
Pages (from-to)12-17
Number of pages6
JournalOncology
Volume43
Issue number1
StatePublished - 1986
Externally publishedYes

Fingerprint

Altretamine
Doxorubicin
Cyclophosphamide
Cisplatin
Carcinoma
Drug Therapy
Therapeutics
Melphalan
Survival
Drug Combinations
Laparotomy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma. / Richman, Carol M; Podczaski, E.; Weiser, P. A.; Herbst, A. L.

In: Oncology, Vol. 43, No. 1, 1986, p. 12-17.

Research output: Contribution to journalArticle

@article{95ab322b299d42b9ba5c4c5c3e8100c6,
title = "Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma",
abstract = "Thirty-six patients with advanced/recurrent epithelial ovarian carcinoma were treated with a combination of hexamethylmelamine, cyclophosphamide, adriamycin, and cis-platinum. In the group of 23 previously untreated patients, 10 of 12 (83{\%}) with measurable disease had objective responses (7 complete, 3 partial). The median survival of the 23 patients exceeded 18 months. After approximately 1 year of chemotherapy, 9 patients with no clinical evidence of disease had a 'second look' laparotomy; 6 of these patients were disease-free. Two of the 6 patients with surgically documented complete responses had bulky ( > 5 cm) disease prior to initiation of chemotherapy and remained disease-free at 22 and 50 months. One of the 6 patients relapsed 5 months after a negative second look. The other patients were alive and disease-free at 18, 46, and 51 months. Only 4 of 13 melphalan-resistant patients (31{\%}) demonstrated an objective response to the 4-drug combination. The median survival was 13 months.",
author = "Richman, {Carol M} and E. Podczaski and Weiser, {P. A.} and Herbst, {A. L.}",
year = "1986",
language = "English (US)",
volume = "43",
pages = "12--17",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma

AU - Richman, Carol M

AU - Podczaski, E.

AU - Weiser, P. A.

AU - Herbst, A. L.

PY - 1986

Y1 - 1986

N2 - Thirty-six patients with advanced/recurrent epithelial ovarian carcinoma were treated with a combination of hexamethylmelamine, cyclophosphamide, adriamycin, and cis-platinum. In the group of 23 previously untreated patients, 10 of 12 (83%) with measurable disease had objective responses (7 complete, 3 partial). The median survival of the 23 patients exceeded 18 months. After approximately 1 year of chemotherapy, 9 patients with no clinical evidence of disease had a 'second look' laparotomy; 6 of these patients were disease-free. Two of the 6 patients with surgically documented complete responses had bulky ( > 5 cm) disease prior to initiation of chemotherapy and remained disease-free at 22 and 50 months. One of the 6 patients relapsed 5 months after a negative second look. The other patients were alive and disease-free at 18, 46, and 51 months. Only 4 of 13 melphalan-resistant patients (31%) demonstrated an objective response to the 4-drug combination. The median survival was 13 months.

AB - Thirty-six patients with advanced/recurrent epithelial ovarian carcinoma were treated with a combination of hexamethylmelamine, cyclophosphamide, adriamycin, and cis-platinum. In the group of 23 previously untreated patients, 10 of 12 (83%) with measurable disease had objective responses (7 complete, 3 partial). The median survival of the 23 patients exceeded 18 months. After approximately 1 year of chemotherapy, 9 patients with no clinical evidence of disease had a 'second look' laparotomy; 6 of these patients were disease-free. Two of the 6 patients with surgically documented complete responses had bulky ( > 5 cm) disease prior to initiation of chemotherapy and remained disease-free at 22 and 50 months. One of the 6 patients relapsed 5 months after a negative second look. The other patients were alive and disease-free at 18, 46, and 51 months. Only 4 of 13 melphalan-resistant patients (31%) demonstrated an objective response to the 4-drug combination. The median survival was 13 months.

UR - http://www.scopus.com/inward/record.url?scp=0022645542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022645542&partnerID=8YFLogxK

M3 - Article

C2 - 3079898

AN - SCOPUS:0022645542

VL - 43

SP - 12

EP - 17

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 1

ER -